2022 World Conference on Lung Cancer (ePosters)-EP07.01-025. Survival Advantage of Pulmonary Metastasectomy in Advanced Melanoma Patients: A Population-Based Study

EP07.01-025. Survival Advantage of Pulmonary Metastasectomy in Advanced Melanoma Patients: A Population-Based Study

Pdf Summary

This study aimed to investigate the survival benefits of pulmonary metastasectomy (PM) in advanced melanoma patients with lung metastasis. The study included 520 patients, of which 18.8% underwent PM and 81.2% did not. The median overall survival (OS) was significantly higher in the PM group compared to the non-PM group (43.0 months vs. 13 months). The median cancer-specific survival (CSS) was not reached in the PM group, while it was 16 months in the non-PM group. The study found that older age, never being married, and not undergoing primary surgical resection were independent prognostic factors for worse OS and CSS. However, sex, and receipt of chemotherapy and/or radiotherapy did not impact survival outcomes. The PM group had a statistically significant survival advantage compared to the non-PM group for both OS and CSS. In addition, the inverse probability treatment weighted (IPTW) analysis confirmed the survival benefits of PM in terms of OS and CSS. The findings suggest that PM can provide survival benefits for certain advanced melanoma patients with lung metastasis and should be considered as part of a multimodality treatment plan. Individualized management is recommended to enhance survival chances for these patients.

Asset Subtitle

Sebawe Syaj

Meta Tag

Speaker Sebawe Syaj

Topic Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

Keywords

pulmonary metastasectomy

advanced melanoma

lung metastasis

survival benefits

overall survival

cancer-specific survival

prognostic factors

primary surgical resection

chemotherapy

radiotherapy